London, UK (PRWEB) April 02, 2015
Across the biopharmaceutical industry, the cancer immunotherapy field is forecast to generate revenue of over USD 80 billion by 2020. The market has been underpinned by the approval of Dendreon’s Provenge for advanced prostate cancer in 2010 and Bristol-Myers’ Yervoy drug for skin cancer melanoma in 2011. Immunotherapy drugs are considered to be more efficient than the traditional options, and they are set to be used for the treatment of a variety (around 60%) of cancer types during the next ten years. These drugs generated close to USD 41.0 billion of revenue as of 2014. By the end of 2020, Nivolumab, Rituxan, Avastin, Revlimid and Xtandi are projected to be the five leading cancer drugs. Bristol-Myers Squibb’s Yervoy, for instance, is expected to have a market value of over USD 1.775 billion by 2020. Opdivo and Keytruda will likely generate sales revenues of USD 4.3 billion and USD 2.9 billion, respectively, in 2019.
At present, over 15 companies are developing 30 various antibody-drug conjugates – a new class of therapeutic agents targeting hematologic malignancies and solid tumors alike. Carrying a chemotherapy drug, the ADCs are deemed to be more effective and efficient in the disease treatment. On the back of shrinking pipelines and a wave of patent expirations, large pharmacos recognised the vaccine marketplace as a potential investment hot spot. The global cancer vaccine market was valued at about USD 4.4 billion and is likely to be estimated at USD 8.4 billion in 2020.
New research report “Global & USA Cancer Immunotherapy Market Analysis to 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors” elaborated by Kelly Scientific Publications is available at MarketPublishers.com.
Title: Global & USA Cancer Immunotherapy Market Analysis to 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors
Published: April, 2015
Price: US$ 3,400.00
The report describes the evolution of such a huge cancer immunotherapy market, including monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapy drugs, by segment, product segment and by company. It provides an all-round overview of the size and segmentation of the market, current trends in cancer immunotherapies, key challenges being faced by drug manufacturers, descriptions of around 23 cancer immunotherapy drugs approved and used, the different immunotherapeutics used for specific cancers, data on the prevalence of cancers that are addressed by cancer immunotherapeutics, top players and the huge potential of therapies undergoing clinical studies. The analysis of the overall worldwide cancer therapeutics market, along with leading market players and the best-selling oncology drugs is provided. The study presents a detailed analysis of the market for cancer immunotherapeutics based on indication, geography, company and drugs. It offers detailed profiles and products (marketed in pipeline) of the 76 companies, mostly from the USA and Europe.
- Insightful overview of the cancer immunotherapy
- Review of today’s status of cancer immunotherapy
- Insights into the key challenges in cancer medicine research.
- Identification of cancer immunotherapeutic drug products.
- Overview of the available immunotherapies for cancer by the indication type.
- Details about cancer incidence and mortality rates.
- Detailed analysis of the global oncology market, covering top 10 companies in oncology drug sales, five major oncology drugs, world oncology therapeutics market based on cancer type.
- Comprehensive examination of the cancer immunotherapy marketplace.
- Granular profiles of companies with their product portfolios.
- Description of cancer immunotherapy market players by product segment.
More new studies by the publisher can be found at Kelly Scientific Publications page.